Delix Therapeutics closes $100 million Series C financing to advance Zalsupindole into Phase II development. The round was led by strategic pharma and SV Health neurodegen fund.
Amount Raised
$100 Million
Round Type
Series C
BostonBiotechnologyData And AnalyticsHealth CareScience And EngineeringInvestors
Description
Delix Therapeutics has successfully closed an oversubscribed Series C financing, raising $100 million. This funding will facilitate the advancement of Zalsupindole into Phase II development and support broader pipeline advancement. The round was led by strategic pharma partners alongside SV Health neurodegeneration fund. This marks a significant milestone for the company's innovative approach to neuroplasticity.
Who to call at Delix Therapeutics, and when
A new round usually means Delix Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Delix Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Delix Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Delix Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Delix Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Delix Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.